中国肿瘤临床 2012, Vol. 39 Issue (23): 1916-1920 DOI: doi:10.3969/j.issn.1000-8179.2012.23.012

凋亡抑制因子Livin 在三阴性乳腺癌中的表达及其判断预后的价值

陈 亮, 戴殿禄, 崔国忠, 杨 猛, 丁明剑

河北省沧州市中心医院肿瘤外二科（河北省沧州市061001）

Protein Expression of Livin in Triple-negative Breast Cancer and Its Value in Prognosis

Liang CHEN, Dianlu DAI, Guozhong CUI, Meng YANG, Mingjian DING

The Second Department of Surgical Oncology, Cangzhou Central Hospital, Cangzhou 061001, China

全文: PDF (1524 KB) HTML (1 KB) 输出: BibTeX | EndNote (RIS) 背景资料

摘要 目的：探讨凋亡抑制因子Livin在三阴性乳腺癌中的表达及与预后的关系，分析三阴性乳腺癌的独立预后影响因素。方法：用免疫组织化学SP法检测90例三阴性乳腺癌、35例癌旁乳腺组织、10例正常乳腺组织中Livin的表达；结合临床病理特征和随访资料，建立Cox 模型进行回归分析。结果：Livin在三阴性乳腺癌中的表达率为57.8% ，在癌旁乳腺组织中的表达率为34.3%，在正常乳腺组织中表达率为0，三者之间差异有统计学意义（P<0.05）。Livin的表达与临床分期、脉管癌栓及腋淋巴结转移均有显著性差异（P<0.05），而与年龄、肿瘤大小、乳腺癌家族史及组织学分级无显著性差异（P>0.05）。 Kaplan-Meier 生存曲线显示，Livin蛋白低表达组患者的无瘤生存时间及总生存时间明显优于Livin蛋白高表达组患者。多因素Cox 回归分析显示，年龄、临床分期、脉管癌栓及腋淋巴结转移情况是影响患者DFS 的独立危险因素；仅临床分期及腋淋巴结转移情况是影响患者总生存时间的独立危险因素；而Livin均被剔除。结论：Livin的异常高表达可能与三阴性乳腺癌的发生、发展及预后有相关性，提示Livin的表达可能成为判断三阴性乳腺癌浸润进展及预后的指标之一。

关键词： 三阴性乳腺癌 Livin 免疫组织化学 预后 多因素分析

Abstract: Objective: To investigate the expression of the apoptosis inhibitor Livin and its correlations in the prognosis of tri -ple-negative breast cancer (TNBC). Methods:The expression of Livin was determined by immunohistochemical Streptavidin-Peroxi-dase method in 90cases with TNBC, 35with paraneoplastic tissues, and 10with normal tissues. The Cox model analysis was estab -lished using clinico-pathological features and follow-up data. Results:The positive expression of Livin was 57.8% in the TNBC tissues and 34.3% in the paraneoplastic breast tissues. No Livin expression was observed in all 10normal tissues, indicating the absence of sta -tistical significance among the groups (P<0.05). The expression of Livin was significantly correlated with clinical stage, lymph-vascu -lar invasion, and axillary lymph node metastasis (P<0.05). The expression of Livin did not show correlations with the patient's age, tu -mor size, family history of breast cancer, and histologic grade (P>0.05). The plotted survival curves by the Kaplan – Meier method dem-onstrated that disease-free survival and overall survival were significantly better in patients with low expression than in patients with high expression of Livin protein. Multivariate Cox regression analysis showed that age, clinical stage, lymph-vascular invasion, and ax-illary lymph node metastasis were independent risk factors affecting the five-year disease-free rate of the patients, whereas clinical stage and axillary lymph node metastasis were independent risk factors affecting the five-year overall rate of the patients. The Livin pro -tein was then rejected. Conclusion:The abnormal expression of Livin is related to the development and prognosis of TNBC, suggesting that the expression of Livin may be used as one of the indicators in determining the progress and prognosis of TNBC.

Key words: Triple-negative breast cancer Livin Immunohistochemistry Prognosis Multivariate analysis

收稿日期: 2012-01-30; 出版日期: 2012-12-15

通讯作者: 戴殿禄 **E-mail:** czddl@tom.com

引用本文:

. 凋亡抑制因子Livin 在三阴性乳腺癌中的表达及其判断预后的价值[J]. 中国肿瘤临床, 2012, 39(23): 1916-1920.

. Protein Expression of Livin in Triple-negative Breast Cancer and Its Value in Prognosis[J]. Chinese Journal of Clinical Oncology, 2012, 39(23): 1916-1920.

链接本文:

http://118.145.16.228:8081/Jweb_zgzllc/CN/doi:10.3969/j.issn.1000-8179.2012.23.012 或 http://118.145.16.228:8081/Jweb_zgzllc/CN/Y2012/V39/I23/1916

没有本文参考文献

[1] 曹 杉,任宝柱,张新伟,韩 颖,张维红,惠珍珍,戚 颖,杨雪娜,任秀宝. **74**例肺癌患者**GVAX**治疗前后外周血树突状细胞变化及其临床意义[J]. 中国肿瘤临床 2012, 39(9): 514-518.

[2] 杜春娟,刘 亮,曹 水,熊艳娟,杜伟娇,齐 静,张 澎,安 阳,任秀宝. 细胞因子诱导的杀伤细胞治疗**87**例非小细胞肺癌临床疗效评价[J]. 中国肿瘤临床, 20 39(9): 519-523.

[3] 李 状,王 琪,张 玮,阳志军,唐步坚,黄明钜,李 力. 卵巢癌组织中二氢叶酸还原酶基因的表达及其临床意义[J]. 中国肿瘤临床, 2012, 39(9): 564-569.

[4] 刘晓东,汪 旭,贾勇圣,王 蕊,佟仲生. 三阴性对小肿块乳腺癌患者预后的影响[J]. 中国肿瘤临床, 2012, 39(9): 578-582.

[5] 王春平,陆荫英,高旭东,王 鋐,白文林,曲建慧,曾 珍,张敏娜,常秀娟. 索拉非尼治疗进展期肝细胞癌的疗效及预后因素分析[J]. 中国肿瘤临床, 2012, 39(9): 592.

[6] 卢素琼,赵化荣,胡尔西旦·尼牙孜,刘 攀,张宋安,张 蕾,包永星. 局部肌层浸润性膀胱癌预后影响因素分析[J]. 中国肿瘤临床, 2012, 39(9): 593-596.

[7] 尹婧婧,周礼鲲,李鸿立,巴 一. 循环肿瘤细胞与乳腺癌患者预后相关性的**Meta**分析[J]. 中国肿瘤临床, 2012, 39(9): 602-606.

[8] 庄 倩，郝良纯，张继红. 左旋门冬酰胺酶杀伤**MOLT-4**细胞的机制研究[J]. 中国肿瘤临床, 2012, 39(8): 421-424.

[9] 杨艳芳，刘 君，姜战胜，顾 林. **VEGF**在三阴性乳腺癌中的表达及临床意义[J]. 中国肿瘤临床, 2012, 39(8): 439-.

[10] 张 寰，周晓颖，张丽娜，钱碧云. 碱基切除修复通路基因**XRCC1**、**hOGG1**多态性与吸烟对肺癌患者生存的影响[J]. 中国肿瘤临床, 2012, 39(8): 447-45

[11] 潘利华，陈雪松，综述，蔡 莉，审校. 乳腺癌预后评估系统的研究进展[J]. 中国肿瘤临床, 2012, 39(8): 472-475.

[12] 王云翔，范 宇，张 勤，王 彤，刘 红. **TopoII$_{\alpha}$**蛋白在不同分子亚型乳腺癌中的表达及其预后价值[J]. 中国肿瘤临床, 2012, 39(7): 382-387.